Disc Medicine Q2 Loss Misses Estimates by 28%; Cash Runway into 2029 and Key Pipeline Milestones on Track
IRON sits 85% above its 52-week low of $40.
Summary
Disc Medicine's Q2 loss of $1.54 per share missed estimates by 28%, but $718 million in cash provides runway into 2029. The FDA aligned that the Phase 3 APOLLO study can support a CRL response, with topline data due in Q4 2026. Initial data from the RESTORE-PV Phase 2 study is now expected in Q3 2026.
Key Events · Earnings and Guidance · IRON
-
Q2 Loss Misses Consensus
Net loss of $59.5 million, or $1.54 per share, compared to consensus estimate of ~$1.20 per share. The miss was driven by higher R&D and SG&A expenses to support pipeline advancement.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities totaled $717.7 million as of June 30, 2026, expected to fund operations into 2029 — well beyond key catalysts including the APOLLO Phase 3 readout and potential FDA decision.
-
FDA Alignment on Bitopertin Path
Completed Type A meeting with FDA; agency aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for the CRL response and potentially support traditional approval. Topline data expected in Q4 2026.
-
Pipeline Catalysts Accelerating
RESTORE-PV Phase 2 study of DISC-3405 fully enrolled with initial data now expected in Q3 2026 (ahead of schedule). End-of-Phase 2 meeting for selcodebart in myelofibrosis anticipated by year-end 2026.
Analysis · IRON · Life Sciences
Disc Medicine posted a Q2 net loss of $1.54 per share, well below the consensus estimate of ~$1.20, as higher operating costs fueled pipeline advancement. Despite the miss, the company closed the quarter with $718 million in cash, extending its runway into 2029—comfortably past the anticipated APOLLO Phase 3 topline readout in Q4 2026 and a potential FDA decision by mid-2027. The FDA's alignment that APOLLO can serve as the basis for the CRL response de-risks the bitopertin regulatory path. Additional pipeline catalysts are now closer: initial data from the fully enrolled RESTORE-PV Phase 2 study is expected in Q3 2026, and an end-of-Phase 2 meeting for selcodebart in myelofibrosis is anticipated by year-end. The earnings miss is a near-term negative, but the strong cash position and multiple upcoming data readouts keep the investment thesis intact.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRON was trading at $73.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $40.00 to $99.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.